Bamco Inc. NY Raises Stake in Certara, Inc. (NASDAQ:CERT)

Bamco Inc. NY lifted its holdings in shares of Certara, Inc. (NASDAQ:CERT - Free Report) by 31.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 315,000 shares of the company's stock after buying an additional 75,000 shares during the period. Bamco Inc. NY owned approximately 0.20% of Certara worth $3,355,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. BNP Paribas Financial Markets purchased a new position in Certara during the 4th quarter worth $2,972,000. Ameriprise Financial Inc. boosted its holdings in shares of Certara by 864.0% in the fourth quarter. Ameriprise Financial Inc. now owns 3,779,655 shares of the company's stock valued at $40,253,000 after acquiring an additional 3,387,590 shares in the last quarter. Algert Global LLC acquired a new position in shares of Certara during the fourth quarter worth about $662,000. ArrowMark Colorado Holdings LLC raised its holdings in Certara by 164.2% during the fourth quarter. ArrowMark Colorado Holdings LLC now owns 6,213,278 shares of the company's stock worth $66,171,000 after purchasing an additional 3,861,674 shares in the last quarter. Finally, Jane Street Group LLC lifted its position in Certara by 60.5% in the fourth quarter. Jane Street Group LLC now owns 236,591 shares of the company's stock valued at $2,520,000 after purchasing an additional 89,198 shares during the period. Hedge funds and other institutional investors own 73.96% of the company's stock.

Certara Price Performance

Certara stock traded up $0.11 during mid-day trading on Friday, hitting $11.98. 1,361,391 shares of the company were exchanged, compared to its average volume of 1,287,242. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. Certara, Inc. has a 12-month low of $8.64 and a 12-month high of $17.76. The business's 50 day simple moving average is $11.67 and its two-hundred day simple moving average is $11.66. The company has a market capitalization of $1.93 billion, a P/E ratio of -59.90, a PEG ratio of 9.29 and a beta of 1.57.

Certara (NASDAQ:CERT - Get Free Report) last released its earnings results on Monday, May 5th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.10 by $0.04. The company had revenue of $106.00 million for the quarter, compared to analyst estimates of $104.44 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The firm's quarterly revenue was up 9.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.10 EPS. Analysts forecast that Certara, Inc. will post 0.28 earnings per share for the current fiscal year.

Analyst Ratings Changes

CERT has been the topic of several recent analyst reports. TD Cowen began coverage on Certara in a research report on Thursday, February 27th. They set a "buy" rating and a $16.00 target price on the stock. Barclays upgraded Certara from an "equal weight" rating to an "overweight" rating and increased their price objective for the stock from $11.00 to $14.00 in a research report on Thursday. JMP Securities reissued a "market perform" rating on shares of Certara in a report on Tuesday. Robert W. Baird upped their price target on shares of Certara from $9.00 to $13.00 and gave the stock a "neutral" rating in a research note on Friday, April 11th. Finally, KeyCorp raised their price objective on shares of Certara from $15.00 to $18.00 and gave the company an "overweight" rating in a research note on Wednesday, April 16th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $15.67.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.